Immunophenotype of myeloid granulocytes in Chinese patients with BCR::ABL1-negative myeloproliferative neoplasms.
Humans
Immunophenotyping
Male
Middle Aged
Female
Granulocytes
/ pathology
Adult
Aged
Flow Cytometry
Fusion Proteins, bcr-abl
/ genetics
Myeloproliferative Disorders
/ genetics
Janus Kinase 2
/ genetics
Thrombocythemia, Essential
/ genetics
Aged, 80 and over
China
Young Adult
Calreticulin
/ genetics
CD11b Antigen
/ genetics
Polycythemia Vera
/ genetics
Mutation
Asian People
/ genetics
East Asian People
Granulocyte
Immunophenotype
Myeloproliferative neoplasm
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
21 May 2024
21 May 2024
Historique:
received:
21
03
2024
accepted:
28
04
2024
medline:
21
5
2024
pubmed:
21
5
2024
entrez:
21
5
2024
Statut:
epublish
Résumé
Typical BCR::ABL1-negative myeloproliferative neoplasms (MPN) are mainly referred to as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofbrosis (PMF). Granulocytes in MPN patients are involved in their inflammation and form an important part of the pathophysiology of MPN patients. It has been shown that the immunophenotype of granulocytes in MPN patients is altered. We used flow cytometry to explore the immunophenotype of MPN patients and correlate it with clinical parameters. The results showed that PMF patients and PV patients had higher CD15+CD11b+ granulocytes than ET patients and normal controls. When grouped by gene mutation, changes in the granulocyte immunophenotype of MPN patients were independent of the JAK2V617F and CALR mutations. There was no significant heterogeneity in immunophenotype between ET patients and Pre-PMF, and between Overt-PMF and Pre-PMF patients. Granulocytes from some MPN patients showed an abnormal CD13/CD16 phenotype with a significant increase in mature granulocytes on molecular and cytomorphological grounds, and this abnormal pattern occurred significantly more frequently in PMF patients than in ET patients. CD15-CD11b- was negatively correlated with WBC and Hb and positively correlated with DIPSS score, whereas high CD10+ granulocytes were significantly and negatively associated with prognostic system IPSS and DIPSS scores in PMF patients. In conclusion, this study demonstrates the landscape of bone marrow granulocyte immunophenotypes in MPN patients. MPN patients, especially those with PMF, have a significant granulocyte developmental overmaturation phenotype. CD10+ granulocytes may be involved in the prognosis of PMF patients.
Identifiants
pubmed: 38771542
doi: 10.1007/s10238-024-01363-7
pii: 10.1007/s10238-024-01363-7
doi:
Substances chimiques
JAK2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106Informations de copyright
© 2024. The Author(s).
Références
Padda J, Khalid K, Yadav J, et al. JAK2 and TET2 mutation in polycythemia vera. Cureus. 2021;13:e17854.
pubmed: 34660059
pmcid: 8502023
Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123:2220–8.
doi: 10.1182/blood-2013-11-537167
pubmed: 24478400
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
doi: 10.1182/blood-2016-03-643544
pubmed: 27069254
Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:915–25.
doi: 10.1002/ajh.23703
pubmed: 25124313
Luque Paz D, Kralovics R, Skoda RC. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023;141:1909–21.
doi: 10.1182/blood.2022017578
pubmed: 36347013
Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28:1472–7.
doi: 10.1038/leu.2014.3
pubmed: 24402162
Carobbio A, Ferrari A, Masciulli A, et al. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019;3:1729–37.
doi: 10.1182/bloodadvances.2019000211
pubmed: 31175128
pmcid: 6560342
Bonicelli G, Abdulkarim K, Mounier M, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol. 2013;160:251–4.
doi: 10.1111/bjh.12117
pubmed: 23151052
Subotički T, Mitrović Ajtić O, Beleslin-Čokić BB, et al. Angiogenic factors are increased in circulating granulocytes and CD34 cells of myeloproliferative neoplasms. Mol Carcinog. 2017;56:567–79.
doi: 10.1002/mc.22517
pubmed: 27341002
Guijarro-Hernández A, Vizmanos JL. Transcriptomic comparison of bone marrow CD34+ cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations. BMC Genom Data. 2023;24:40.
doi: 10.1186/s12863-023-01142-5
pubmed: 37550636
pmcid: 10408115
Coucelo M, Caetano G, Sevivas T, et al. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients. Int J Hematol. 2014;99:32–40.
doi: 10.1007/s12185-013-1475-9
pubmed: 24277659
Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96(13):4261–6.
doi: 10.1182/blood.V96.13.4261
pubmed: 11110700
Torregrosa JM, Ferrer-Marín F, Lozano ML, et al. Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation. Br J Haematol. 2016;172:813–5.
doi: 10.1111/bjh.13539
pubmed: 26132594
Guo H, Chen X, Tian R, et al. Frequencies, laboratory features, and granulocyte activation in Chinese patients with CALR-mutated myeloproliferative neoplasms. PLoS ONE. 2015;10:e0138250.
doi: 10.1371/journal.pone.0138250
pubmed: 26375990
pmcid: 4574314
Edelmann B, Gupta N, Schnoeder TM, et al. JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation. J Clin Invest. 2018;128:4359–71.
doi: 10.1172/JCI90312
pubmed: 30024857
pmcid: 6159978
Wang W, Liu W, Fidler T, et al. Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 mice. Circ Res. 2018;123:e35–47.
doi: 10.1161/CIRCRESAHA.118.313283
pubmed: 30571460
pmcid: 6309796
Riva G, Nasillo V, Ottomano AM, et al. Multi-parametric flow cytometry for MRD monitoring in hematologic malignancies: clinical applications and new challenges. Cancers (Basel). 2021;13:4582.
doi: 10.3390/cancers13184582
pubmed: 34572809
Bento LC, Correia RP, Pitangueiras Mangueira CL, et al. The use of flow cytometry in myelodysplastic syndromes: a review. Front Oncol. 2017;7:270.
doi: 10.3389/fonc.2017.00270
pubmed: 29188193
pmcid: 5694750
Bento LC, Correia RP, Pitangueiras Mangueira CL, et al. The use of flow cytometry in myelodysplastic syndromes: a review. Front Oncol. 2017;7:270.
doi: 10.3389/fonc.2017.00270
pubmed: 29188193
pmcid: 5694750
Hasserjian RP, Germing U, Malcovati L. Diagnosis and classification of myelodysplastic syndromes. Blood. 2023;142:2247–57.
doi: 10.1182/blood.2023020078
pubmed: 37774372
Bassan VL, Barretto GD, de Almeida FC, et al. Philadelphia-negative myeloproliferative neoplasms display alterations in monocyte subpopulations frequency and immunophenotype. Med Oncol. 2022;39:223.
doi: 10.1007/s12032-022-01825-6
pubmed: 36175590
pmcid: 9522456
Feng B, Verstovsek S, Jorgensen JL, et al. Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis. Am J Clin Pathol. 2010;133:314–20.
doi: 10.1309/AJCPNC99DHXIOOTD
pubmed: 20093242
Mannelli F, Bencini S, Coltro G, et al. Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. Am J Hematol. 2022;97:846–55.
doi: 10.1002/ajh.26548
pubmed: 35338671
pmcid: 9682857
Van Acker HH, Capsomidis A, Smits EL, et al. CD56 in the immune system: more than a marker for cytotoxicity? Front Immunol. 2017;8:892.
doi: 10.3389/fimmu.2017.00892
pubmed: 28791027
pmcid: 5522883
Skog MS, Nystedt J, Korhonen M, et al. Expression of neural cell adhesion molecule and polysialic acid in human bone marrow-derived mesenchymal stromal cells. Stem Cell Res Ther. 2016;7:113.
doi: 10.1186/s13287-016-0373-5
pubmed: 27528376
pmcid: 4986182
Raspadori D, Damiani D, Lenoci M, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia. 2001;15(8):1161–4.
doi: 10.1038/sj.leu.2402174
pubmed: 11480556
Sasca D, Szybinski J, Schüler A, et al. NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML. Blood. 2019;133:2305–19.
doi: 10.1182/blood-2018-12-889725
pubmed: 30814062
Huang W, Liu R-R-Y, et al. Role of flow cytometry in the diagnosis of chronic myeloid Leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023;31:1327–32.
pubmed: 37846680
Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123(22):e123–33.
doi: 10.1182/blood-2014-02-554634
pubmed: 24740812
pmcid: 4041169
Liu J, Wang F, Luo F. The role of JAK/STAT pathway in fibrotic diseases: molecular and cellular mechanisms. Biomolecules. 2023;13:119.
doi: 10.3390/biom13010119
pubmed: 36671504
pmcid: 9855819
Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–901.
doi: 10.1182/blood-2008-07-170449
pubmed: 18988864
Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703–8.
doi: 10.1182/blood-2009-09-245837
pubmed: 20008785
Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124:1062–9.
doi: 10.1182/blood-2014-05-578435
pubmed: 24986690
pmcid: 4133481
Pei Y-Q, Wu Y, Wang F, et al. Prognostic value of CALR vs JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. Ann Hematol. 2016;95:1391–8.
doi: 10.1007/s00277-016-2712-0
pubmed: 27376361
Li B, Xu J, Wang J, et al. Calreticulin mutations in Chinese with primary myelofibrosis. Haematologica. 2014;99:1697–700.
doi: 10.3324/haematol.2014.109249
pubmed: 24997152
pmcid: 4222480
Li B, Zhang P, Feng G, et al. Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis. Blood Cancer J. 2016;6:e505.
doi: 10.1038/bcj.2016.116
pubmed: 27935577
pmcid: 5223151
Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36:310–8.
doi: 10.1200/JCO.2017.76.4886
pubmed: 29226763
Marini O, Costa S, Bevilacqua D, et al. Mature CD10 and immature CD10 neutrophils present in G-CSF-treated donors display opposite effects on T cells. Blood. 2017;129:1343–56.
doi: 10.1182/blood-2016-04-713206
pubmed: 28053192